Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
News|Articles|February 13, 2019
- Drug Topics March 2019
- Volume 163
- Issue 3
Xofluza for Acute Uncomplicated Influenza
Author(s)Drew Boxler
Advertisement
Xofluza (baloxavir marboxil, Genetech)
Indications: acute uncomplicated influenza in patients 12+, <48hr symptomatic
Dosage:
- 40-80kg body = 40 mg
- 80kg+ = 80 mg
Contraindications: history of hypersensitivity to baloxair marboxil or any of its ingredients
Articles in this issue
over 7 years ago
Coping with Patient Deathover 7 years ago
Opinion: Why Change Is Like a Hemorrhoidectomyover 7 years ago
Pharmacists Want More Time with Patientsover 7 years ago
The Pros and Cons of Switching to a Health Systemover 7 years ago
Early Planning is Key to Retirement and Successionover 7 years ago
Dietary Supplements Need Evidence and Evaluationover 7 years ago
Reconnect to Reinvigorateover 7 years ago
Pharmacy Education for the 21st Centuryover 7 years ago
How to Achieve Balance in Work and in Lifeover 7 years ago
Case Studies in StabilityAdvertisement
Related to this article
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: PBM Reform, Provider Status Key in Stopping Pharmacy Deserts
2
Pfizer Reports Strong Phase 2 Data for 25-Valent Pediatric PCV
3
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
4
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
5